ORAQIX bulk active fine chemical vendors

Subscribe to access the full database, or Start Trial
Vendor	Vendor Homepage	Vendor Sku	API Url
J&H Chemical Co.,ltd	⤷ Start Trial	JH25365	⤷ Start Trial
RR Scientific	⤷ Start Trial	R516664	⤷ Start Trial
Starshine Chemical	⤷ Start Trial	2023-05-5H00471	⤷ Start Trial
>Vendor	>Vendor Homepage	>Vendor Sku	>API Url

Last updated: July 30, 2025

Introduction

Oraqix (lidocaine and prilocaine) is a local anesthetic gel administered orally for periodontal procedures. As a complex pharmaceutical product, its formulation relies heavily on high-quality Active Pharmaceutical Ingredients (APIs). The sourcing of APIs for Oraqix involves stringent regulatory standards, quality controls, and supply chain considerations. This article evaluates the global landscape of API sources for Oraqix, incorporating market dynamics, key suppliers, regulatory factors, and implications for pharmaceutical manufacturers.

API Composition and Manufacturing Requirements for Oraqix

Oraqix’s therapeutic efficacy hinges on two APIs: Lidocaine and Prilocaine. Both are amide-type local anesthetics that require precise manufacturing processes, purity levels, and adherence to Good Manufacturing Practices (GMP).

Lidocaine is widely used in dental and topical anesthetics, with a substantial global supply chain. Prilocaine is similarly prevalent but less abundant than Lidocaine, often raising supply considerations. The APIs must meet pharmacopoeial standards such as USP, EP, or BP.

Key manufacturing attributes include:

High chemical purity (>99%)
Absence of impurities and residual solvents
Stable supply for consistent formulation batches
Compliance with regulatory frameworks (FDA, EMA, etc.)

Global API Suppliers for Oraqix

The API market for both lidocaine and prilocaine is mature, with multiple suppliers globally. These suppliers are classified into primary API manufacturers, contract manufacturing organizations (CMOs), and regional suppliers.

Major Lidocaine API Suppliers

Colorcon (India)
- One of the leading producers of pharmaceutical-grade APIs, including lidocaine.
- Offers high-purity APIs that are compliant with global standards.
- Benefits from India’s robust pharmaceutical manufacturing infrastructure.
Hubei Biocause Pharmaceutical Co., Ltd. (China)
- Noted for large-volume lidocaine production.
- Offers competitive pricing and extensive manufacturing capacity.
- Subject to quality audits to meet international regulatory standards.
Lida Pharmaceutical (China)
- Supplies both raw APIs and intermediates.
- Recognized for consistent quality and comprehensive regulatory documentation.
Motor Chemie AG (Switzerland)
- A longstanding European API producer with high-quality standards.
- Provides advanced analytical support and regulatory compliance.
Akorn, LLC (USA)
- Focuses on U.S. and global markets.
- Known for rigorous quality assurance processes.

Major Prilocaine API Suppliers

Chengdu Hanhong Pharmaceutical Co., Ltd. (China)
- Leading producer of prilocaine APIs with global reach.
- Known for cost-effective bulk production adhering to GMP.
Korea Pharmaceutical and Bio-Pharma (South Korea)
- Provides high-quality prilocaine APIs with ISO and GMP certification.
- Offers regulatory support for international markets.
Lina Chemicals Ltd. (India)
- Supplies prilocaine APIs aligned with global pharmacopoeias.
- Focuses on high purity standards.
Viloron (India)
- Contract manufacturer with significant prilocaine API capacity.
- Certified for GMP, with suitable documentation for regulatory submissions.
Nanchang Rewin Chemical Co., Ltd. (China)
- Supplier of APIs with proven track records in pharmaceutical manufacturing.

Regulatory and Quality Considerations

In sourcing APIs for Oraqix, compliance with regulatory standards is paramount. The FDA, EMA, and other regulatory agencies demand:

Certifications such as GMP compliance
Batch documentation and stability data
Certificates of Analysis (CoA) confirming specifications
Residual solvent and impurity profiles

Suppliers often undergo audits, certifications, and ongoing quality assurance processes. Additionally, sourcing from suppliers with a strong track record reduces supply chain risks and regulatory hurdles.

Supply Chain Dynamics and Risk Management

The geographic distribution of API suppliers introduces both opportunities and risks:

Diversification Enhances Security: Relying on multiple suppliers across regions reduces risks linked to geopolitical issues, natural disasters, or factory disruptions.
Regional Regulations Influence Sourcing: Strict import/export controls in regions such as the US (FDA), EU (EMA), and China impact availability and pricing.
Market Trends: Growing demand, especially from emerging markets, exerts pressure on supplier capacity, leading to potential shortages or price fluctuations.

Manufacturers often establish strategic partnerships with established API producers, leverage multiple supply sources, and foster long-term agreements to ensure consistent supply chains.

Emerging Trends and Future Outlook

Biotechnological Advances: Although current APIs are chemical syntheses, there is a gradual shift toward biotechnological methods in the synthesis of local anesthetics, driven by regulatory and reproducibility advantages.
Sustainability Considerations: Increasing emphasis on environmentally friendly manufacturing processes influences API sourcing decisions.
Supply Chain Resilience: The COVID-19 pandemic underscored vulnerabilities in API supply chains, prompting companies to reevaluate supplier portfolios and stock buffer policies.

The future of API sourcing for Oraqix will likely involve increased transparency, digital tracking, and strategic stockpiling to mitigate supply disruptions.

Conclusion

The sourcing landscape for APIs used in Oraqix reflects a mature, globally distributed market characterized by a diverse array of manufacturers specializing in lidocaine and prilocaine. Ensuring high-quality, GMP-compliant APIs requires careful vendor qualification, regulatory due diligence, and robust supply chain management. Companies seeking stability and compliance should prioritize suppliers with proven regulatory credentials and diversified sourcing strategies.

Key Takeaways

The primary APIs for Oraqix, lidocaine and prilocaine, are produced globally, with major suppliers in China, India, the US, and Switzerland.
Regulatory compliance (GMP, ISO, pharmacopoeial standards) is a critical factor in API sourcing.
Diversifying API sources mitigates risks associated with regional disruptions and supply shortages.
Emerging manufacturing innovations and sustainability initiatives are influencing future API sourcing strategies.
Proactive supply chain management is essential to ensure continuous availability of high-quality APIs for Oraqix formulations.

FAQs

1. What are the top API suppliers for lidocaine used in Oraqix?
Major suppliers include Colorcon (India), Hubei Biocause Pharmaceutical (China), Motor Chemie AG (Switzerland), and Akorn LLC (USA). These firms provide high-quality, GMP-compliant APIs suitable for pharmaceutical formulations.

2. How do regulatory standards influence API sourcing for Oraqix?
APIs must meet stringent standards such as USP, EP, or BP, alongside GMP certification. Suppliers with validated quality systems and comprehensive documentation facilitate regulatory approvals and batch consistency.

3. What are the risks associated with sourcing APIs from China and India?
Potential risks include regulatory variability, quality consistency, and geopolitical issues. However, reputable suppliers adhere to international standards, mitigating these concerns. Diversification reduces dependence on any single region.

4. Are there sustainable or eco-friendly trends in API manufacturing for Oraqix?
Yes. Manufacturers are increasingly adopting green chemistry principles, reducing solvent use, managing waste effectively, and improving energy efficiency to meet sustainability goals and regulatory expectations.

5. How might supply chain disruptions impact the availability of APIs for Oraqix?
Disruptions such as pandemics, trade restrictions, or factory issues can cause shortages. Strategic inventory management, multiple sourcing, and supplier audits are critical mitigation strategies.

References

[1] U.S. Pharmacopeia. (2022). "Lidocaine and Prilocaine Monographs."
[2] PharmaSphere. (2023). "Global API Market Reports."
[3] European Medicines Agency. (2022). "Guidelines on API Manufacturing."
[4] IQVIA. (2023). "Pharmaceutical API Supply Chain Analysis."
[5] IndustryWatch. (2022). "Emerging Trends in API Sustainability."

Bulk Pharmaceutical API Sources for ORAQIX